ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1186/s10020-021-00400-5
Published Online: 2021-10-29
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sun, Dantong
Teng, Fei
Xing, Puyuan
Li, Junling http://orcid.org/0000-0002-7361-325X
Text and Data Mining valid from 2021-10-29
Version of Record valid from 2021-10-29
Article History
Received: 24 August 2021
Accepted: 14 October 2021
First Online: 29 October 2021
Declarations
:
: Not applicable.
: All authors approved for the publication.
: The authors declared no conflict of interests.